The Times Australia
Health

.

Could we one day get vaccinated against the gastro bug norovirus? Here’s where scientists are at

  • Written by Grant Hansman, Senior Research Fellow, Institute for Biomedicine and Glycomics, Griffith University

Norovirus is the leading cause[1] of acute gastroenteritis outbreaks worldwide. It’s responsible for roughly one in every five cases[2] of gastro annually.

Sometimes dubbed the “winter vomiting bug” or the “cruise ship virus”, norovirus – which causes vomiting and diarrhoea[3] – is highly transmissible. It spreads via contact with an infected person or contaminated surfaces. Food can also be contaminated with norovirus.

While anyone can be infected, groups such as young children, older adults and people who are immunocompromised are more vulnerable[4] to getting very sick with the virus. Norovirus infections lead to about 220,000 deaths[5] globally each year.

Norovirus outbreaks also lead to massive economic burdens[6] and substantial health-care costs.

Although norovirus was first identified more than 50 years ago[7], there are no approved vaccines or antiviral treatments for this virus. Current treatment is usually limited to rehydration, either by giving fluids orally[8] or through an intravenous drip[9].

So if we’ve got vaccines for so many other viruses – including COVID, which emerged only a few years ago – why don’t we have one for norovirus?

An evolving virus

One of the primary barriers to developing effective vaccines lies in the highly dynamic nature of norovirus evolution. Much like influenza viruses, norovirus shows continuous genetic shifts, which result in changes to the surface of the virus particle[10].

In this way, our immune system can struggle to recognise and respond when we’re exposed to norovirus, even if we’ve had it before.

Compounding this issue, there are at least 49 different norovirus genotypes[11].

Both genetic diversity and changes in the virus’ surface mean the immune response to norovirus is unusually complex. An infection will typically only give someone immunity to that specific strain and for a short time – usually between six months and two years[12].

All of this poses challenges for vaccine design. Ideally, potential vaccines must not only induce strong, long-lasting immunity, but also maintain efficacy across the vast genetic diversity of circulating noroviruses.

Recent progress

Progress in norovirus vaccinology[13] has accelerated over the past couple of decades. While researchers are considering multiple strategies to formulate and deliver vaccines, a technology called VLP-based vaccines is at the forefront.

VLP stands for virus-like particles[14]. These synthetic particles, which scientists developed using a key component of the norovirus (called the major caspid protein), are almost indistinguishable from the natural structure of the virus.

When given as a vaccine, these particles elicit an immune response resembling that generated by a natural infection with norovirus – but without the debilitating symptoms of gastro.

What’s in the pipeline?

One bivalent VLP vaccine[15] (“bivalent” meaning it targets two different norovirus genotypes) has progressed through multiple clinical trials. This vaccine showed some protection[16] against moderate to severe gastroenteritis in healthy adults.

However, its development recently suffered a significant setback. A phase two clinical trial in infants failed to show it effectively protected against moderate or severe acute gastroenteritis[17]. The efficacy of the vaccine in this trial was only 5%.

In another recent phase two trial, an oral norovirus vaccine[18] did meet its goals[19]. Participants who took this pill were 30% less likely to develop norovirus compared to those who received a placebo.

This oral vaccine uses a modified adenovirus[20] to deliver the norovirus VLP gene sequence to the intestine to stimulate the immune system.

With the success of mRNA vaccines during the COVID pandemic, scientists are also exploring this platform for norovirus.

Messenger ribonucleic acid (mRNA) is a type of genetic material that gives our cells instructions to make proteins[21] associated with specific viruses. The idea is that if we subsequently encounter the relevant virus, our immune system will be ready to respond.

Moderna, for example, is developing an mRNA vaccine[22] which primes the body with norovirus VLPs.

The theoretical advantage of mRNA-based vaccines lies in their rapid adaptability. They will potentially allow annual updates to match circulating strains.

Researchers have also developed alternative vaccine approaches using just the norovirus “spikes” located on the virus particle[23]. These spikes contain crucial structural features, allowing the virus to infect our cells, and should elicit an immune response similar to VLPs. Although still in early development, this is another promising strategy.

Separate to vaccines, my colleagues and I have also discovered a number of natural compounds that could have antiviral properties against norovirus. These include simple lemon juice[24] and human milk oligosaccharides[25] (complex sugars found in breast milk).

Although still in the early stages, such “inhibitors” could one day be developed into a pill to prevent norovirus from causing an infection.

Where to from here?

Despite recent developments, we’re still probably at least three years away from any norovirus vaccine hitting the market.

Several key challenges remain before we get to this point. Notably, any successful vaccine must offer broad cross-protection against genetically diverse and rapidly evolving strains. And we’ll need large, long-term studies to determine the durability of protection and whether boosters might be required.

Norovirus is often dismissed as only a mild nuisance, but it can be debilitating – and for the most vulnerable, deadly. Developing a safe and effective norovirus vaccine is one of the most pressing and under-addressed needs in infectious disease prevention.

A licensed norovirus vaccine could drastically reduce workplace and school absenteeism, hospitalisations and deaths. It could also bolster our preparedness against future outbreaks of gastrointestinal pathogens.

References

  1. ^ the leading cause (www.cdc.gov)
  2. ^ one in every five cases (journals.plos.org)
  3. ^ vomiting and diarrhoea (www.cdc.gov)
  4. ^ more vulnerable (www.cdc.gov)
  5. ^ 220,000 deaths (journals.plos.org)
  6. ^ economic burdens (journals.plos.org)
  7. ^ 50 years ago (journals.asm.org)
  8. ^ fluids orally (www.health.nsw.gov.au)
  9. ^ an intravenous drip (www.ncbi.nlm.nih.gov)
  10. ^ surface of the virus particle (journals.asm.org)
  11. ^ 49 different norovirus genotypes (www.microbiologyresearch.org)
  12. ^ six months and two years (wwwnc.cdc.gov)
  13. ^ norovirus vaccinology (pmc.ncbi.nlm.nih.gov)
  14. ^ virus-like particles (journals.asm.org)
  15. ^ bivalent VLP vaccine (academic.oup.com)
  16. ^ some protection (www.sciencedirect.com)
  17. ^ against moderate or severe acute gastroenteritis (ir.hillevax.com)
  18. ^ oral norovirus vaccine (www.science.org)
  19. ^ meet its goals (investors.vaxart.com)
  20. ^ a modified adenovirus (insight.jci.org)
  21. ^ instructions to make proteins (cepi.net)
  22. ^ mRNA vaccine (www.nature.com)
  23. ^ located on the virus particle (journals.asm.org)
  24. ^ lemon juice (www.sciencedirect.com)
  25. ^ human milk oligosaccharides (journals.asm.org)

Read more https://theconversation.com/could-we-one-day-get-vaccinated-against-the-gastro-bug-norovirus-heres-where-scientists-are-at-258909

Times Magazine

Why Social Media Marketing Matters for Businesses in Australia

Today social media is a big part of daily life. All over Australia people use Facebook, Instagram, TikTok , LinkedIn and Twitter to stay connected, share updates and find new ideas. For businesses this means a great chance to reach new customers and...

Building an AI-First Culture in Your Company

AI isn't just something to think about anymore - it's becoming part of how we live and work, whether we like it or not. At the office, it definitely helps us move faster. But here's the thing: just using tools like ChatGPT or plugging AI into your wo...

Data Management Isn't Just About Tech—Here’s Why It’s a Human Problem Too

Photo by Kevin Kuby Manuel O. Diaz Jr.We live in a world drowning in data. Every click, swipe, medical scan, and financial transaction generates information, so much that managing it all has become one of the biggest challenges of our digital age. Bu...

Headless CMS in Digital Twins and 3D Product Experiences

Image by freepik As the metaverse becomes more advanced and accessible, it's clear that multiple sectors will use digital twins and 3D product experiences to visualize, connect, and streamline efforts better. A digital twin is a virtual replica of ...

The Decline of Hyper-Casual: How Mid-Core Mobile Games Took Over in 2025

In recent years, the mobile gaming landscape has undergone a significant transformation, with mid-core mobile games emerging as the dominant force in app stores by 2025. This shift is underpinned by changing user habits and evolving monetization tr...

Understanding ITIL 4 and PRINCE2 Project Management Synergy

Key Highlights ITIL 4 focuses on IT service management, emphasising continual improvement and value creation through modern digital transformation approaches. PRINCE2 project management supports systematic planning and execution of projects wit...

The Times Features

Could we one day get vaccinated against the gastro bug norovirus? Here’s where scientists are at

Norovirus is the leading cause[1] of acute gastroenteritis outbreaks worldwide. It’s responsible for roughly one in every five cases[2] of gastro annually. Sometimes dubbed ...

Does running ruin your knees? And how old is too old to start?

You’ve probably heard that running is tough on your knees – and even that it can cause long-term damage. But is this true? Running is a relatively high-impact activity. Eve...

Jetstar announces first ever Brisbane to Rarotonga flights with launch fares from just $249^ one-way

Jetstar will start operating direct flights between Brisbane and Rarotonga, the stunning capital island of the Cook Islands, in May 2026, with launch sale fares available today...

Introducing the SE 2 and Mini hair dryers from Laifen

The Mane Attractions for Professional Styling at Home Without the Price Tag Fast, flawless hair is now possible with the launch of Laifen’s two professional quality hair dryers th...

Home Gym Recovery Routines: What Pro Athletes Do After Workouts

Training is only half the equation. What you do after your workout has just as much impact on your progress, performance, and long-term health. Professional athletes know this, w...

Flipping vs. Holding: Which Investment Strategy Is Right for You?

Are you wondering whether flipping a property or holding onto it is the better investment strategy? The answer isn’t one-size-fits-all. Both strategies have distinct advantages a...